Martin Bhatt

Martin Bhatt focuses on the regulatory science of immunotherapy biomarkers at the NCI, developing frameworks for clinical validation and approval of companion diagnostics for cancer immunotherapy. His work has contributed to FDA guidance documents on the use of TMB, PD-L1, and MSI as regulatory endpoints in oncology trials. He has helped define analytical and clinical validation standards for novel immunotherapy biomarkers. His contributions bridge bench science and regulatory policy to accelerate biomarker-driven drug approval in oncology.